Indometacin farnesil

Indometacin farnesil
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
MetabolismTo indometacin
Elimination half-life1.5 hours
ExcretionRenal
Identifiers
IUPAC name
  • (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.242.585
Edit this at Wikidata
Chemical and physical data
FormulaC34H40ClNO4
Molar mass562.15 g·mol−1
3D model (JSmol)
SMILES
  • CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC=C(C)CCC=C(C)CCC=C(C)C
InChI
  • InChI=1S/C34H40ClNO4/c1-23(2)9-7-10-24(3)11-8-12-25(4)19-20-40-33(37)22-30-26(5)36(32-18-17-29(39-6)21-31(30)32)34(38)27-13-15-28(35)16-14-27/h9,11,13-19,21H,7-8,10,12,20,22H2,1-6H3/b24-11+,25-19+ checkY
  • Key:CFIGYZZVJNJVDQ-LMJOQDENSA-N checkY
  (verify)

Indometacin farnesil (INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon, respectively.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.